DALLAS, September 8, 2011 /PRNewswire/ —
The report “
Global Clinical Trials Market (2007 – 2010)” analyses
the total number of clinical trials conducted globally from 2007 to
2010 by phases, study design, indications, and major market
drivers, restraints, and opportunities for the clinical trials
market in North America, South America, Europe, and Asia.
Browse market data tables and in-depth TOC on Global
Clinical Trials Market (2007 – 2010)
http://www.marketsandmarkets.com/Market-Reports/clinical-trials-market-405.html
Early buyers will receive 10% customization of
reports.
Clinical trials market now witness a paradigm shift. Naïve
heterogeneous patient populations in the developing nations are
opening up new avenues for the
clinical trials market. Developing countries also offer faster
go to market which is triggering major pharmaceutical companies to
direct their investment in these regions. Apart from this,
stringent regulations and tight R&D budgets in the
Pharma-Biotech industry are also forcing companies to move to east.
This scenario has further boosted the alliances between the
pharma-biotech companies and the clinical research organizations,
with the latter accounting for major chunk of the trials
conducted.
Today, emerging countries account for the largest share of the
phase II/III (prime stages) clinical trials conducted globally with
major focus on oncology, Alzheimer’s, metabolic and cardiovascular
diseases. Support from the respective government bodies is one of
the major factors affecting the clinical trials market. Clinical
trials sponsored by the industry have a much higher share i
‘/>”/>
SOURCE
